Brachytherapy is included in APM unless this has been changed from the final rule published Sept 2020 "Given that physicians sometimes contract with others to supply and administer brachytherapy radioactive sources (or radioisotopes), we explained in the proposed rule that we considered omitting these services from the episode payment. After considering either including or excluding brachytherapy radioelements from the RO Model, we proposed to include brachytherapy radioactive elements, rather than omit these services, from the episodes because they are generally furnished in HOPD (hospital outpatient departments) and the hospitals are usually the purchasers of the brachytherapy radioactive elements. When not furnished in HOPDs, these services are furnished in ASC (ambulatory surgical centers) , which we noted were proposed to be excluded from the Model.
See the
final rule from CMS.
There is a lot of stuff in that document but from what I can tell brachytherapy is generally included in the APM.
"We proposed at 84 FR 34502 through 34503 to include the following RT modalities in the Model: Various types of external beam RT, including 3- dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), and proton beam therapy (PBT); intraoperative radiotherapy (IORT); image-guided radiation therapy (IGRT); and brachytherapy. We proposed to include all of these modalities because they are the most commonly used to treat the 17 proposed cancer types..."
"We thank commenters for their support of including brachytherapy as well as those commenters expressing their concerns and their suggestions. An episode-based payment covers all included RT services furnished to an RO beneficiary during a 90-day episode. Bundled episode payment rates are premised on the notion of averages. The cases including a combination of EBRT and brachytherapy described by the commenters are part of the set of historical episodes included in the averages that determine the national base rates and contribute to how payment amounts are valued, and, therefore, an adjustment for multiple modalities that include brachytherapy is not warranted at this time. Also, the case mix and historical experience adjustments help account for the costlier beneficiary populations in the participant-specific episode payment amounts. We will be monitoring for change in treatment patterns throughout the Model performance period and will consider modifications to the pricing methodology in future years of the Model should it be warranted. We believe that including brachytherapy in the Model supports this modality as high value, and also that including it preserves the goal of the Model in establishing a true bundled approach to radiotherapy that is also site neutral and modality agnostic. And, we believe that the proposed and finalized pricing methodology and subsequent national base rates for each cancer type accounts for the cost of brachytherapy as a primary modality and if furnished in conjunction with EBRT. We recognize the billing complexity when separate RT providers and RT suppliers furnish the brachytherapy and EBRT and will address this in billing guidance provided to RO participants. We will monitor for any unintended consequences of the Model on multimodality treatment that includes both external beam and brachytherapy. As for the concern that errors in the claims data (specifically those that commenters believe stem from incorrect attribution of CPT®/HCPCS codes to certain modalities) underrepresented the true cost of delivering a combination of modalities like EBRT and brachytherapy, we rely on the data submitted on claims by providers and suppliers to be accurate per Medicare rules and regulations. We are finalizing the provision to include brachytherapy in the RO Model."